The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Venous Insufficiency

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Venous Insufficiency


High impact information on Venous Insufficiency


Chemical compound and disease context of Venous Insufficiency

  • Although potentially lethal if unrecognized and treated simply as venous insufficiency, chronic therapy with warfarin offers palliation and prolongs life [10].
  • PURPOSE: The North American Subfascial Endoscopic Perforator Surgery (NASEPS) Registry was established to evaluate the safety, feasibility, and efficacy of minimally invasive endoscopic Linton operations for treatment of chronic venous insufficiency [11].
  • METHODS: Indexes of venous valvular function, including venous filling time, 90% of venous refilling time, and simulated ambulatory venous pressure, were measured in 11 greyhounds before intervention (Control) and after hind limb venous valvulotomy, which produces chronic venous insufficiency [12].
  • CONCLUSION: The demonstration of a significant reduction in Ang II and NE contractile activities and the important reduction of that of ET-1 in the diseased veins as compared with the control tissues extends the previous observations regarding the impairment of smooth muscle contractility in primary chronic venous insufficiency [13].
  • Daflon 500 mg, is a micronized purified flavonoid fraction, containing 90% w/w diosmin and 10% w/w of flavonoids expressed as hesperidin, used clinically in the treatment of chronic venous insufficiency and hemorrhoidal disease [14].

Biological context of Venous Insufficiency


Anatomical context of Venous Insufficiency


Gene context of Venous Insufficiency


Analytical, diagnostic and therapeutic context of Venous Insufficiency


  1. Drug treatment of haemorrhoids. Misra, M.C., Imlitemsu, n.u.l.l. Drugs (2005) [Pubmed]
  2. The immediate effects of endovenous diode 808-nm laser in the greater saphenous vein: morphologic study and clinical implications. Corcos, L., Dini, S., De Anna, D., Marangoni, O., Ferlaino, E., Procacci, T., Spina, T., Dini, M. J. Vasc. Surg. (2005) [Pubmed]
  3. The prevalence of hyperhomocysteinemia, methylene tetrahydrofolate reductase C677T mutation, and vitamin B12 and folate deficiency in patients with chronic venous insufficiency. Sam, R.C., Burns, P.J., Hobbs, S.D., Marshall, T., Wilmink, A.B., Silverman, S.H., Bradbury, A.W. J. Vasc. Surg. (2003) [Pubmed]
  4. Altered proliferative responses of dermal fibroblasts to TGF-beta1 may contribute to chronic venous stasis ulcer. Lal, B.K., Saito, S., Pappas, P.J., Padberg, F.T., Cerveira, J.J., Hobson, R.W., Durán, W.N. J. Vasc. Surg. (2003) [Pubmed]
  5. The posterior stocking seam approach to radical subfascial clipping of perforating veins. Blumenberg, R.M., Gelfand, M.L. Am. J. Surg. (1978) [Pubmed]
  6. Norrie disease gene mutation in a large Costa Rican kindred with a novel phenotype including venous insufficiency. Rehm, H.L., Gutiérrez-Espeleta, G.A., Garcia, R., Jiménez, G., Khetarpal, U., Priest, J.M., Sims, K.B., Keats, B.J., Morton, C.C. Hum. Mutat. (1997) [Pubmed]
  7. An animal model of venous hypertension: the role of inflammation in venous valve failure. Pascarella, L., Schmid-Schönbein, G.W., Bergan, J. J. Vasc. Surg. (2005) [Pubmed]
  8. Regarding "Optimal therapy for advanced chronic venous insufficiency". Escribano, J.M. J. Vasc. Surg. (2003) [Pubmed]
  9. Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency. Saito, S., Trovato, M.J., You, R., Lal, B.K., Fasehun, F., Padberg, F.T., Hobson, R.W., Durán, W.N., Pappas, P.J. J. Vasc. Surg. (2001) [Pubmed]
  10. Occult antithrombin III deficiency: a potentially lethal complication of the postphlebitic limb. Phifer, T.J., Mills, G.M. J. Vasc. Surg. (1990) [Pubmed]
  11. Safety, feasibility, and early efficacy of subfascial endoscopic perforator surgery: a preliminary report from the North American registry. Gloviczki, P., Bergan, J.J., Menawat, S.S., Hobson, R.W., Kistner, R.L., Lawrence, P.F., Lumsden, A., O'Donnell, T.F., DePalma, R.G., Murray, J., Pigott, J.P., Schanzer, H., Ascer, E., Kalman, P., Calligaro, K.D., Ballard, J.L., Cambria, R.A., Rhee, R.Y., Rubin, B.G., Ilstrup, D.M., Harmsen, W.S., Canton, L.G. J. Vasc. Surg. (1997) [Pubmed]
  12. Valve transplantation to the canine popliteal vein: the utility of a distal arteriovenous fistula and the hemodynamic result of a single functional valve. Dalsing, M.C., Lalka, S.G., Zukowski, A.J., Unthank, J.L., Sawchuk, A.P., Cikrit, D.F. J. Vasc. Surg. (1994) [Pubmed]
  13. Effects of vasoactive agents in healthy and diseased human saphenous veins. Rizzi, A., Quaglio, D., Vasquez, G., Mascoli, F., Amadesi, S., Calò, G., Regoli, D., Zamboni, P. J. Vasc. Surg. (1998) [Pubmed]
  14. Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. Garner, R.C., Garner, J.V., Gregory, S., Whattam, M., Calam, A., Leong, D. Journal of pharmaceutical sciences. (2002) [Pubmed]
  15. Leg ulcers in Klinefelter's syndrome--further evidence for an involvement of plasminogen activator inhibitor-1. Zollner, T.M., Veraart, J.C., Wolter, M., Hesse, S., Villemur, B., Wenke, A., Werner, R.J., Boehncke, W.H., Jost, S.S., Scharrer, I., Kaufmann, R. Br. J. Dermatol. (1997) [Pubmed]
  16. Haemostatic factors and risk of varicose veins and chronic venous insufficiency: Edinburgh Vein Study. Lee, A.J., Lowe, G.D., Rumley, A., Ruckley, C.V., Fowkes, F.G. Blood Coagul. Fibrinolysis (2000) [Pubmed]
  17. Retinoblastoma protein: a molecular regulator of chronic venous insufficiency. Pappas, P.J., Gwertzman, G.A., DeFouw, D.O., Padberg, F.T., Silva, M.B., Durán, W.N., Hobson, R.W. J. Surg. Res. (1998) [Pubmed]
  18. Pharmacodynamics and pharmacokinetics of Veliten (rutine, alpha-tocopherol and ascorbic acid) in patients with chronic venous insufficiency. Auteri, A., Pasqui, A.L., Bruni, F., Di Renzo, M., Bova, G., Chiarion, C., Delchambre, J. International journal of clinical pharmacology research. (1994) [Pubmed]
  19. Endovenous laser ablation of the saphenous vein for treatment of venous insufficiency and varicose veins: early results from a large single-center experience. Perkowski, P., Ravi, R., Gowda, R.C., Olsen, D., Ramaiah, V., Rodriguez-Lopez, J.A., Diethrich, E.B. J. Endovasc. Ther. (2004) [Pubmed]
  20. Capillary underperfusion in chronic venous insufficiency: a cause for leg ulceration? Luetolf, O., Bull, R.H., Bates, D.O., Mortimer, P.S. Br. J. Dermatol. (1993) [Pubmed]
  21. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders. Struckmann, J.R., Nicolaides, A.N. Angiology. (1994) [Pubmed]
  22. Changes of cytokeratin expression in the epidermis with chronic venous insufficiency. Peschen, M., Grenz, H., Lahayé, T., Brand-Saberi, B., Simon, J.C., Schöpf, E., Vanscheidt, W. VASA (1997) [Pubmed]
  23. Modulation of urokinase-type and tissue-type plasminogen activator occurs at an early stage of progressing stages of chronic venous insufficiency. Peschen, M., Rogers, A.A., Chen, W.Y., Vanscheidt, W. Acta Derm. Venereol. (2000) [Pubmed]
  24. Severity of venous insufficiency is related to the density of microvascular deposition of PAI-1, uPA and von Willebrand factor. Kolbach, D.N., Hamulyák, K., Prins, M.H., Neumann, H.A., Cleutjens, J.P. VASA (2004) [Pubmed]
  25. Patterns of epidermal growth factor receptor, basic fibroblast growth factor and transforming growth factor-beta3 expression in skin with chronic venous insufficiency. Peschen, M., Grenz, H., Grothe, C., Schöpf, E., Vanscheidt, W. European journal of dermatology : EJD. (1998) [Pubmed]
  26. A new method for the assessment of venous insufficiency in primary varicose veins using near-infrared spectroscopy. Hosoi, Y., Yasuhara, H., Shigematsu, H., Aramoto, H., Komiyama, T., Muto, T. J. Vasc. Surg. (1997) [Pubmed]
  27. Target selection for surgical intervention in severe chronic venous insufficiency: comparison of duplex scanning and phlebography. Depalma, R.G., Kowallek, D.L., Barcia, T.C., Cafferata, H.T. J. Vasc. Surg. (2000) [Pubmed]
  28. Physiologic similarities between extremities with varicose veins and with chronic venous insufficiency utilizing air plethysmography. Cordts, P.R., Hartono, C., LaMorte, W.W., Menzoian, J.O. Am. J. Surg. (1992) [Pubmed]
  29. Surgical management of chronic venous insufficiency. Löfgren, K.A. Acta chirurgica Scandinavica. Supplementum. (1988) [Pubmed]
  30. Post-thrombotic syndrome after total hip or knee arthroplasty: incidence in patients with asymptomatic deep venous thrombosis. Schindler, O.S., Dalziel, R. Journal of orthopaedic surgery (Hong Kong) (2005) [Pubmed]
WikiGenes - Universities